Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Doxycycline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 known ✓ | P09237 | 1/20 | 0.69 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.69 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.70 |
| ▸ | USP2 | O75604 | 6/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.69 |
| ▸ | MMP2 | P08253 | 1/20 | 0.69 |
| ▸ | MMP3 | P08254 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 7/20 | 0.64 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.64 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxycycline Anhydrous SCHEMBL6627427 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL12011108 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL9574618 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL12194961 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL7850301 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL2614206 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL16726317 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL2614979 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL66828 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL19270311 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | NSUN3, NSUN2, RNMT | MMP7 1455/4885MMP8 1918/4885MMP13 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.